other:Article Title: AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4
Article Snippet: Antibodies used were: JAK2 monoclonal antibody (Jak2 (D2E12)XP #3230 Cell Signaling Technology, Danvers, MA, USA); MPL polyclonal antibody (TpoR/MPL (AF1016) R&D, Minneapolis, MN, USA); phospho-STAT5 polyclonal antibody (phospho-Stat5 (Tyr694) #9351 Cell Signaling Technology, Danvers, MA, USA); phospho-STAT3 polyclonal antibody (phospho-Stat3 (Ser727) #9134 Cell Signaling Technology, Danvers, MA, USA); phospho-ERK1/2 polyclonal antibody (phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) #9101 Cell Signaling Technology, Danvers, MA, USA); total ERK1/2 polyclonal antibody (p44/42 MAP Kinase antibody #9102 Cell Signaling Technology, Danvers, MA, USA), CD147 monoclonal antibody (EMMPRIN/CD147 (B5) sc-46700, Santa Cruz Biotechnology, CA, USA); MCT4 monoclonal antibody (MCT4 (F-10) sc-376101, Santa Cruz, CA, USA).
Article Title: AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4.
Article Snippet: Antibodies used were: JAK2 monoclonal antibody (Jak2 (D2E12)XP #3230 Cell Signaling Technology, Danvers, MA, USA); MPL polyclonal antibody (TpoR/MPL (AF1016) R&D, Minneapolis, MN, USA); phospho-STAT5 polyclonal antibody (phospho-Stat5 (Tyr694) #9351 Cell Signaling Technology, Danvers, MA, USA); phospho-STAT3 polyclonal antibody (phospho-Stat3 (Ser727) #9134 Cell Signaling Technology, Danvers, MA, USA); phosphoERK1/2 polyclonal antibody (phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) #9101 Cell Signaling Technology, Danvers, MA, USA); total ERK1/2 polyclonal antibody (p44/42 MAP Kinase antibody #9102 Cell Signaling Technology, Danvers, MA, USA), CD147 monoclonal antibody (EMMPRIN/CD147 (B5) sc-46700, Santa Cruz Biotechnology, CA, USA); MCT4 monoclonal antibody (MCT4 (F-10) sc-376101, Santa Cruz, CA, USA).
|